154 related articles for article (PubMed ID: 29238994)
21. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients.
Yamagata T; Kusuhara H; Morishita M; Takayama K; Benameur H; Sugiyama Y
Drug Metab Dispos; 2007 Jul; 35(7):1142-8. PubMed ID: 17446265
[TBL] [Abstract][Full Text] [Related]
22. Regional difference in intestinal drug absorption as a measure for the potential effect of P-glycoprotein efflux transporters.
Ashmawy SM; El-Gizawy SA; El Maghraby GM; Osman MA
J Pharm Pharmacol; 2019 Mar; 71(3):362-370. PubMed ID: 30362574
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, molecular modeling, in vitro and in vivo biological evaluation of potent anthranilamide derivatives as dual P-glycoprotein and CYP3A4 inhibitors.
Said AM; Mansour YE; Soliman RR; Islam R; Fatahala SS
Eur J Med Chem; 2024 Jul; 273():116492. PubMed ID: 38762918
[TBL] [Abstract][Full Text] [Related]
24. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031.
Woo JS; Lee CH; Shim CK; Hwang SJ
Pharm Res; 2003 Jan; 20(1):24-30. PubMed ID: 12608532
[TBL] [Abstract][Full Text] [Related]
25. Modulation of oral bioavailability of anticancer drugs: from mouse to man.
Schellens JH; Malingré MM; Kruijtzer CM; Bardelmeijer HA; van Tellingen O; Schinkel AH; Beijnen JH
Eur J Pharm Sci; 2000 Dec; 12(2):103-10. PubMed ID: 11102737
[TBL] [Abstract][Full Text] [Related]
26. Effects of roxithromycin on the pharmacokinetics of loratadine after oral and intravenous administration of loratadine in rats.
Li C; Kim CS; Yang JY; Park YJ; Choi JS
Eur J Drug Metab Pharmacokinet; 2008; 33(4):231-6. PubMed ID: 19230596
[TBL] [Abstract][Full Text] [Related]
27. P-glycoprotein (P-gp)-mediated efflux limits intestinal absorption of the Hsp90 inhibitor SNX-2112 in rats.
Liu H; Sun H; Wu Z; Zhang X; Wu B
Xenobiotica; 2014 Aug; 44(8):763-8. PubMed ID: 24555822
[TBL] [Abstract][Full Text] [Related]
28. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
van Asperen J; van Tellingen O; Sparreboom A; Schinkel AH; Borst P; Nooijen WJ; Beijnen JH
Br J Cancer; 1997; 76(9):1181-3. PubMed ID: 9365166
[TBL] [Abstract][Full Text] [Related]
29. Discovery of a Flavonoid FM04 as a Potent Inhibitor to Reverse P-Glycoprotein-Mediated Drug Resistance in Xenografts and Improve Oral Bioavailability of Paclitaxel.
Kan JWY; Yan CSW; Wong ILK; Su X; Liu Z; Chan TH; Chow LMC
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499627
[TBL] [Abstract][Full Text] [Related]
30. Investigation of the functional role of P-glycoprotein in limiting the oral bioavailability of lumefantrine.
Wahajuddin ; Raju KS; Singh SP; Taneja I
Antimicrob Agents Chemother; 2014; 58(1):489-94. PubMed ID: 24189249
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cell.
Li YS; Yang X; Zhao DS; Cai Y; Huang Z; Wu R; Wang SJ; Liu GJ; Wang J; Bao XZ; Ye XY; Wei B; Cui ZN; Wang H
Eur J Med Chem; 2021 Apr; 216():113336. PubMed ID: 33725657
[TBL] [Abstract][Full Text] [Related]
32. Effect of a thiolated polymer on oral paclitaxel absorption and tumor growth in rats.
Föger F; Malaivijitnond S; Wannaprasert T; Huck C; Bernkop-Schnürch A; Werle M
J Drug Target; 2008 Feb; 16(2):149-55. PubMed ID: 18274935
[TBL] [Abstract][Full Text] [Related]
33. Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin.
Hong SP; Yang JS; Han JY; Ha SI; Chung JW; Koh YY; Chang KS; Choi DH
J Pharm Pharmacol; 2011 Jan; 63(1):129-35. PubMed ID: 21189658
[TBL] [Abstract][Full Text] [Related]
34. Mechanism of inhibition of P-glycoprotein mediated efflux by Pluronic P123/F127 block copolymers: relationship between copolymer concentration and inhibitory activity.
Wei Z; Yuan S; Hao J; Fang X
Eur J Pharm Biopharm; 2013 Feb; 83(2):266-74. PubMed ID: 23089310
[TBL] [Abstract][Full Text] [Related]
35. Role of P-glycoprotein in intestinal absorption of FB2, a promising Abl/Src dual tyrosine kinase inhibitor.
Huang K; Hu J; Li X; Li Y
Drug Metab Pharmacokinet; 2012; 27(5):486-94. PubMed ID: 22447116
[TBL] [Abstract][Full Text] [Related]
36. HM30181A, a potent P-glycoprotein inhibitor, potentiates the absorption and
Zeng W; Kwan Law BY; Wai Wong VK; Bik Chan DS; Fai Mok SW; Ying Gao JJ; Yan Ho RK; Liang X; Li JH; Lee MT; Yoon WL; Smolinski MP; Nam Lau JY; Kei Lam CW; Fok M
Cancer Biol Med; 2020 Nov; 17(4):986-1001. PubMed ID: 33299648
[TBL] [Abstract][Full Text] [Related]
37. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
Kimura Y; Aoki J; Kohno M; Ooka H; Tsuruo T; Nakanishi O
Cancer Chemother Pharmacol; 2002 Apr; 49(4):322-8. PubMed ID: 11914912
[TBL] [Abstract][Full Text] [Related]
38. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.
Washington CB; Duran GE; Man MC; Sikic BI; Blaschke TF
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Nov; 19(3):203-9. PubMed ID: 9803961
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of P-Glycoprotein Mediated Efflux of Paclitaxel by Coumarin Derivatives in Cancer Stem Cells: An In Silico Approach.
Tripathi A; Misra K
Comb Chem High Throughput Screen; 2016; 19(6):497-506. PubMed ID: 27185570
[TBL] [Abstract][Full Text] [Related]
40. Enhanced intestinal absorption of daidzein by borneol/menthol eutectic mixture and microemulsion.
Shen Q; Li X; Li W; Zhao X
AAPS PharmSciTech; 2011 Dec; 12(4):1044-9. PubMed ID: 21842308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
